SAN ANTONIO, Oct. 4, 2018 /PRNewswire/ -- The InforMing the PAthway of COPD Treatment (IMPACT) study was conducted to assess the benefits of triple versus dual therapy in patients with COPD. In a study at CHEST, researchers found that regardless of baseline reversibility, the usage of triple dual therapies significantly reduced the annual rate and moderate-to-severe and severe exacerbations, improved lung function and overall quality of life in patients.
The randomized, double-blind, parallel-group, global study was conducted in 10,355 symptomatic patients with COPD with a history of moderate-to-severe exacerbations over a 52-week period. During the screening, patient was defined as reversible through differences shown between their pre- and post-albuterol assessments of forced expiratory volume in 1 second (FEV1) of ?12 percent and ?200 mL. Researchers also assessed the effect of baseline reversibility on treatment response with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) and with FF/VI and UMEC/VI. The lung function and quality of life (QoL) of patients were measured by St George Respiratory Questionnaire (SGRQ) and observed for FF/UMEC/VI over UMEC/VI independent of reversibility status at screening.
During screening, 18 percent of patients demonstrated reversibility. In both reversible and nonreversible patients, there was a statistically significant reduction in the rate of moderate and severe exacerbations with FF/UMEC/VI as compared to UMEC/VI. They also found a reduction in the risk of having a moderate/severe exacerbation and the risk of having a severe exacerbation in both groups of patients. Quality of life was also improved in both reversible and non-reversible patients.
Further results from these two studies will be shared at CHEST Annual Meeting 2018 in San Antonio on Wednesday, Oct. 10, 9:30 a.m. to 9:45 a.m., at the Henry B. Gonzalez Convention Centre, Room 207A. The study abstracts can be viewed on the journal CHEST® website.
ABOUT CHEST 2018
CHEST 2018 is the 84th annual meeting for the American College of Chest Physicians held Oct. 6 to Oct. 10, 2018, in San Antonio, Texas. The American College of Chest Physicians, publisher of the journal CHEST®, is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research and team-based care. Its mission is to champion the prevention, diagnosis and treatment of chest diseases through education, communication and research. It serves as an essential connection to clinical knowledge and resources for its 19,000 members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For more information about CHEST 2018, visit chestmeeting.chestnet.org, or follow CHEST meeting hashtag, #CHEST2018, on social media.
Media contact: Andrea Camino, [email protected], 224-521-9513
Advertisement
The randomized, double-blind, parallel-group, global study was conducted in 10,355 symptomatic patients with COPD with a history of moderate-to-severe exacerbations over a 52-week period. During the screening, patient was defined as reversible through differences shown between their pre- and post-albuterol assessments of forced expiratory volume in 1 second (FEV1) of ?12 percent and ?200 mL. Researchers also assessed the effect of baseline reversibility on treatment response with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) and with FF/VI and UMEC/VI. The lung function and quality of life (QoL) of patients were measured by St George Respiratory Questionnaire (SGRQ) and observed for FF/UMEC/VI over UMEC/VI independent of reversibility status at screening.
Advertisement
During screening, 18 percent of patients demonstrated reversibility. In both reversible and nonreversible patients, there was a statistically significant reduction in the rate of moderate and severe exacerbations with FF/UMEC/VI as compared to UMEC/VI. They also found a reduction in the risk of having a moderate/severe exacerbation and the risk of having a severe exacerbation in both groups of patients. Quality of life was also improved in both reversible and non-reversible patients.
Further results from these two studies will be shared at CHEST Annual Meeting 2018 in San Antonio on Wednesday, Oct. 10, 9:30 a.m. to 9:45 a.m., at the Henry B. Gonzalez Convention Centre, Room 207A. The study abstracts can be viewed on the journal CHEST® website.
ABOUT CHEST 2018
CHEST 2018 is the 84th annual meeting for the American College of Chest Physicians held Oct. 6 to Oct. 10, 2018, in San Antonio, Texas. The American College of Chest Physicians, publisher of the journal CHEST®, is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research and team-based care. Its mission is to champion the prevention, diagnosis and treatment of chest diseases through education, communication and research. It serves as an essential connection to clinical knowledge and resources for its 19,000 members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For more information about CHEST 2018, visit chestmeeting.chestnet.org, or follow CHEST meeting hashtag, #CHEST2018, on social media.
Media contact: Andrea Camino, [email protected], 224-521-9513
View original content:http://www.prnewswire.com/news-releases/triple-dual-therapy-significantly-improves-lung-function-quality-of-life-in-copd-patients-300724616.html
SOURCE American College of Chest Physicians
